You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Healus Pharma expects an OO3 phase three major depressive disorder readout later this quarter, plans a 2028 NDA filing and approval, and reported approximately $165 million on its balance sheet.
On October 26, 2026, Helus Pharma Inc. said co-founders Eric So and Paul Glavine stepped down from executive and consulting roles while remaining directors, and appointed Mark Lawson independent Chair effective immediately.
Helus Pharma Inc. announced that CEO Michael Halstead will participate in a fireside chat at the Guggenheim Healthcare Innovation Conference, webcast live on Monday, November 9, 2026 at 3:00 p.m. EDT.
Helus Pharma announced that co-founders Eric So and Paul Glavine stepped down from executive and consulting roles while remaining directors; Eric So was named Chairman Emeritus, and Mark Lawson became independent Chair effective immediately.
Healus Pharma expects Phase 3 top-line results later this quarter, plans HLP-004’s next clinical study for the first quarter of 2027, and expects to advance an HLP-005 preclinical candidate in the second half of 2027.
Helus Pharma expects HLP003’s APPROACH Phase 3 topline data in Q4 2026 and plans to initiate an HLP004 Phase 2 monotherapy study for GAD in Q1 2027.
Helus Pharma appointed Suresh Durgam, M.D., to its Board of Directors, bringing CNS drug-development and regulatory experience; the appointment is subject to approval of Cboe Canada.
Helus Pharma will host an investor presentation on October 21, 2026 at 9:00 a.m. EDT, covering HLP003 in Phase 3 development for major depressive disorder and HLP004 in Phase 2 development for generalized anxiety disorder.
Helus Pharma Inc. changed its legal name from Cybin Inc. effective October 1, 2026, following shareholder approval on September 22, 2026. Its common shares continue trading on Nasdaq Global Market and Cboe Canada under ticker “HELP.”
Helus Pharma Inc. changed its legal name from Cybin Inc. effective October 1, 2026, following shareholder approval on September 22, 2026. Its common shares will continue trading as “HELP,” with CUSIP 423492107 and ISIN CA4234921076.
Helus Pharma Inc. shareholders approved a legal name change from Cybin Inc., fixed the board at eight directors and appointed Zeifmans LLP auditor on September 22, 2026; the name change is effective October 1, 2026.
Helus Pharma CEO Michael Halstead will participate in a fireside chat at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026 at 9:00 a.m. EDT.
Helus Pharma presented four posters at Psych Congress 2026 evaluating HLP003 as an adjunctive treatment for major depressive disorder, including 12-month efficacy, psychedelic-experience and expanded-safety analyses, plus an overview of the ongoing Phase 3 PARADIGM program.
